In 2009, one-third of the over-50 male population in the U.S. showed symptoms of benign prostatic hyperplasia (BPH).

The most common forms of treatment for such symptoms are transurethral resection of the prostate (TURP) and laser treatment. TURP was the most widely accepted treatment method in 2009, as it has been for the past three decades. However, it is expected that laser treatment will account for more than 50% of interventional treatments for BPH by 2014.

BPH is caused by the benign growth of the prostate, which causes obstruction and irritation to the bladder at first, but can lead to further complications if left untreated.

Read more about BPH and the interesting market shift from TURP use to laser treatment in iData Research’s new article in Healthcare Digital, a global, online news source for healthcare leaders.

Will Laser Treatment Become the Gold Standard for Interventional Treatment of BPH?